For Immediate Release
ISK Announces Approval in Japan for BRENDA™, the first therapeutic drug for Pancreatitis in Dogs.
• JMAFF approves BRENDA™ (fuzapladib sodium hydrate), the first drug of its kind for use by
veterinarians in Japan to safely and effectively reduce the clinical signs associated with acute
pancreatitis in dogs.
• ISK is seeking FDA approval in the United States and has been assigned an INAD file number
(Investigational New Animal Drug) for further clinical studies.
• With ISK’s advanced technology platform and leading-edge R&D in organic chemicals, the company
plans to bring new innovative products to the US and other global markets.
OSAKA, Japan, September 28 2018 – Ishihara Sangyo Kaisha, Ltd. (“ISK”) today announced that their
first animal health product, BRENDA™ (fuzapladib sodium hydrate) has been approved by the
Japanese Ministry of Agriculture, Forestry and Fisheries (JMAFF) for use by veterinarians in
Japan for the reduction of clinical signs associated with acute pancreatitis in dogs. BRENDA will
be distributed in Japan by ZENOAQ (Nippon Zenyaku Kogyo Co., LTD.), one of the leading companies
for the sales of animal pharmaceuticals in the Japanese market.
"Pancreatitis is often treated by addressing the symptoms. BRENDA has a critical drug efficacy for
acute pancreatitis, allowing for a speedier recovery and decreased likelihood of
long-term damage," explains Dr.Hiroshi Shikama, General Manager of the Research and
Development Division at ISK Animal Health Headquarters.
BRENDA™ is ISK’s first animal health pharmaceutical drug. It is being launched first in the
Japanese market, with the intention of obtaining approval in other markets over time. With ISK’s
advanced technology platform and leading-edge R&D in organic chemicals, the company plans to become
a strong player in the growing animal health industry by bringing new innovative products to the US
and global markets. ISK is in the process of obtaining FDA approval in the United States.
Click For more information on BRENDA™